News | May 05, 2026
NIFTY Pharma remains resilient amid mixed market sentiment
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
Topiramate is indicated as a treatment of epilepsy and migraine
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
The company has reported total income of Rs. 701 crores during the period ended December 31, 2022
The proceeds of the issue has been/will be reinvested in the company and to meet its own business requirements.
Subscribe To Our Newsletter & Stay Updated
